The adverse outcome pathway concept: A pragmatic tool in toxicology

Toxicology

Volumn 312, Issue 1, 2013, Pages 158-165

  Vinken, Mathieu ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Adverse outcome pathway; Chemical risk assessment; In vitro test development; Mechanistic toxicology; Prioritization strategies; Quantitative structure activity relationship

Indexed keywords

CHOLESTEROL; LIPID; LIVER X RECEPTOR; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

ADVERSE OUTCOME; ADVERSE OUTCOME PATHWAY; CHOLESTASIS; CLINICAL ASSESSMENT TOOL; DRUG INDUCED DISEASE; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL STUDY; FATTY LIVER; FIBROGENESIS; HUMAN; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; INFLAMMATION; INTRAHEPATIC BILE DUCT; LIVER FIBROSIS; LIVER INJURY; MITOCHONDRIAL PERMEABILITY; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SKIN ALLERGY; SKIN SENSITIZATION; STELLATE CELL; STRUCTURE ACTIVITY RELATION;

5′-NT; 5′-NUCLEOTIDASE; ADVERSE OUTCOME (PATHWAY(S)); ADVERSE OUTCOME PATHWAY; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALP; ALT; AO(P)(S); ASPARTATE AMINOTRANSFERASE; AST; BILE SALT EXPORT PUMP; BSEP; CAR; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; CD36; CHEMICAL RISK ASSESSMENT; CHREBP; CONSTITUTIVE ANDROSTANE RECEPTOR; CYP2B10/3A4/7A1; CYTOCHROME P450 2B10/3A4/7A1; DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; DIRECT PEPTIDE REACTIVITY ASSAY; DPRA; FARNESOID X RECEPTOR; FAS; FATTY ACID SYNTHASE; FATTY ACID TRANSLOCASE; FXR; GAMMA-GLUTAMYL TRANSPEPTIDASE; GGT; HCLAT; HUMAN CELL LINE ACTIVATION TEST; IN VITRO TEST DEVELOPMENT; LIVER X RECEPTOR; LXR; MECHANISTIC TOXICOLOGY; MIE; MITOCHONDRIAL PERMEABILITY PORE; MOLECULAR INITIATING EVENT; MPP; MRP2/3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2/3; MUSST; MYELOID U937 SKIN SENSITIZATION TEST; NTCP; OATP1B1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC SOLUTE TRANSPORTER Α/Β; OSTΑ/Β; PREGNANE X RECEPTOR; PRIORITIZATION STRATEGIES; PXR; QSAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SCD1; SHP; SMALL HETERODIMERIC PARTNER; SODIUM/TAUROCHOLATE COTRANSPORTER; SREBP-1C; STEAROYL-COENZYME A DESATURASE 1; STEROL RESPONSE ELEMENT BINDING PROTEIN 1C; SULT2A1; TGF-Β1; TRANSFORMING GROWTH FACTOR BETA 1; UGT2B4; URIDINE 5′-DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B4;

ANIMALS; CHOLESTASIS; FATTY LIVER; HEPATIC STELLATE CELLS; HUMANS; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICOLOGY;

EID: 84884179017     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.08.011     Document Type: Review

References (53)

1. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen K.E., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F.Y., Boobis A., Brandon E., Bremer S., Broschard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S.B., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfuhler S., Phrakonkham P., Piersma A., Poth A., Prieto P., Repetto G., Rogiers V., Schoeters G., Schwarz M., Serafimova R., Tähti H., Testai E., van Delft J., van Loveren H., Vinken M., Worth A., Zaldivar J.M. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 2011, 85:367-485.
2. Amacher D.E. The mechanistic basis for the induction of hepatic steatosis by xenobiotics. Expert Opin. Drug Metab. Toxicol. 2011, 7:949-965.
3. Andersen M.E., Clewell R., Bhattacharya S. Developing in vitro tools sufficient by themselves for 21st century risk assessment. Towards the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing 2012, vol. 2:347-360. Imprimerie Mouzet, France.
4. Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29:730-741.
5. Anon., n.d. (consulted August 2013). http://caat.jhsph.edu/.
6. Anon., n.d. (consulted August 2013). http://www.seurat-1.eu/.
7. Ashikaga T., Yoshida Y., Hirota M., Yoneyama K., Itagaki H., Sakaguchi H., Miyazawa M., Ito Y., Suzuki H., Toyoda H. Development of an in vitro skin sensitization test using human cell lines: the human Cell Line Activation Test (h-CLAT). I. Optimization of the h-CLAT protocol. Toxicol. In Vitro 2006, 20:767-773.
8. Begriche K., Massart J., Robin M.A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 2011, 54:773-794.
9. Bogdanffy M.S., Daston G., Faustman E.M., Kimmel C.A., Kimmel G.L., Seed J., Vu V. Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop. Toxicol. Sci. 2001, 61:18-31.
10. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332(6037):1519-1523.
11. Enoch S.J., Madden J.C., Cronin M.T. Identification of mechanisms of toxic action for skin sensitisation using a SMARTS pattern based approach. SAR QSAR Environ. Res. 2008, 19:555-578.
12. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
13. Friedman S.L. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:425-436.
14. Gerberick G.F., Vassallo J.D., Foertsch L.M., Price B.B., Chaney J.G., Lepoittevin J.P. Quantification of chemical peptide reactivity for screening contact allergens: a classification tree model approach. Toxicol. Sci. 2007, 97:417-427.
15. Gerberick F., Aleksic M., Basketter D., Casati S., Karlberg A.T., Kern P., Kimber I., Lepoittevin J.P., Natsch A., Ovigne J.M., Rovida C., Sakaguchi H., Schultz T. Chemical reactivity measurement and the predictive identification of skin sensitisers. The report and recommendations of ECVAM Workshop 64. Altern. Lab. Anim. 2008, 36:215-242.
16. Gerner I., Barratt M.D., Zinke S., Schlegel K., Schlede E. Development and prevalidation of a list of structure-activity relationship rules to be used in expert systems for prediction of the skin-sensitising properties of chemicals. Altern. Lab. Anim. 2004, 32:487-509.
17. Hill A.B. The environment and disease: association or causation?. Proc. R. Soc. Med. 1965, 58:295-300.
18. Hirano H., Kurata A., Onishi Y., Sakurai A., Saito H., Nakagawa H., Nagakura M., Tarui S., Kanamori Y., Kitajima M., Ishikawa T. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol. Pharm. 2006, 2:252-265.
19. Hofmann A.F. Bile acids and the enterohepatic circulation. The Liver: Biology and Pathobiology 2009, 289-304. Wiley-Blackwell, Oxford. I.M. Arias, H.J. Alter, J.L. Boyer, D.E. Cohen, N. Fausto, D.A. Shafritz, A.W. Wolkoff (Eds.).
20. Honorio K.M., Salum L.B., Garratt R.C., Polikarpov I., Andricopulo A.D. Two- and three-dimensional quantitative structure-activity relationships studies on a series of liver x receptor ligands. Open Med. Chem. J. 2008, 2:87-96.
21. Judson R., Kavlock R., Martin M., Reif D., Houck K., Knudsen T., Richard A., Tice R.R., Whelan M., Xia M., Huang R., Austin C., Daston G., Hartung T., Fowle J.R., Wooge W., Tong W., Dix D. Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 2013, 30:51-56.
22. Julien E., Boobis A.R., Olin S.S. The key events dose-response framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. Crit. Rev. Food Sci. Nutr. 2009, 49:682-689.
23. Kavlock R., Dix D. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. J. Toxicol. Environ. Health B Crit. Rev. 2010, 13:197-217.
24. Kimber I., Basketter D.A., Berthold K., Butler M., Garrigue J.L., Lea L., Newsome C., Roggeband R., Steiling W., Stropp G., Waterman S., Wiemann C. Skin sensitization testing in potency and risk assessment. Toxicol. Sci. 2001, 59:198-208.
25. Landesmann B., Goumenou M., Munn S., Whelan M. Description of prototype modes-of-action related to repeated dose toxicity. JRC Scientific and Policy Report 75689 2012.
26. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 2011, 25:195-206.
27. Maxwell G., Aeby P., Ashikaga T., Bessou-Touya S., Diembeck W., Gerberick F., Kern P., Marrec-Fairley M., Ovigne J.M., Sakaguchi H., Schroeder K., Tailhardat M., Teissier S., Winkler P. Skin sensitisation: the Colipa strategy for developing and evaluating non-animal test methods for risk assessment. ALTEX 2011, 28:50-55.
28. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
29. NRC Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, The National Academies Press, Washington, DC.
30. OECD Proposal for a template and guidance on developing and assessing the completeness of adverse outcome pathways 2012.
31. OECD The adverse outcome pathway for skin sensitization initiated by covalent binding to proteins. Part I: Scientific evidence. Series on testing and assessment No. 168 2012.
32. Padda M.S., Sanchez M., Akhtar A.J., Boyer J.L. Drug-induced cholestasis. Hepatology 2011, 53:1377-1387.
33. Python F., Goebel C., Aeby P. Assessment of the U937 cell line for the detection of contact allergens. Toxicol. Appl. Pharmacol. 2007, 220:113-124.
34. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J. Clin. Pathol. 2009, 62:481-492.
35. Roberts D.W., Aptula A.O., Patlewicz G., Pease C. Chemical reactivity indices and mechanism-based read-across for non-animal based assessment of skin sensitisation potential. J. Appl. Toxicol. 2008, 28:443-454.
36. Saito H., Osumi M., Hirano H., Shin W., Nakamura R., Ishikawa T. Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J. 2009, 11:581-589.
37. Sakaguchi H., Ashikaga T., Miyazawa M., Yoshida Y., Ito Y., Yoneyama K., Hirota M., Itagaki H., Toyoda H., Suzuki H. Development of an in vitro skin sensitization test using human cell lines; human Cell Line Activation Test (h-CLAT). II. An inter-laboratory study of the h-CLAT. Toxicol. In Vitro 2006, 20:774-784.
38. Schoemaker M.H., Conde de la Rosa L., Buist-Homan M., Vrenken T.E., Havinga R., Poelstra K., Haisma H.J., Jansen P.L., Moshage H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 2004, 39:1563-1573.
39. Seed J., Carney E.W., Corley R.A., Crofton K.M., DeSesso J.M., Foster P.M., Kavlock R., Kimmel G., Klaunig J., Meek M.E., Preston R.J., Slikker W., Tabacova S., Williams G.M., Wiltse J., Zoeller R.T., Fenner-Crisp P., Patton D.E. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 2005, 35:664-672.
40. Simon-Hettich B., Rothfuss A., Steger-Hartmann T. Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology 2006, 224:156-162.
41. US EPA Guidelines for carcinogen risk assessment 2005, Washington, DC.
42. Uter W., Johansen J.D., Börje A., Karlberg A.T., Lidén C., Rastogi S., Roberts D., White I.R. Categorization of fragrance contact allergens for prioritization of preventive measures: clinical and experimental data and consideration of structure-activity relationships. Contact Dermatitis 2013, (in press).
43. Vinken M., Pauwels M., Ates G., Vivier M., Vanhaecke T., Rogiers V. Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Arch. Toxicol. 2012, 86:405-412.
44. Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol. Sci. 2013, (in press).
45. Vocanson M., Hennino A., Rozières A., Poyet G., Nicolas J.F. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 2009, 64:1699-1714.
46. Wagner M., Zollner G., Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 2009, 51:565-580.
47. Warner D.J., Chen H., Cantin L.D., Kenna J.G., Stahl S., Walker C.L., Noeske T. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab. Dispos. 2012, 40:2332-2341.
48. Watanabe K.H., Andersen M.E., Basu N., Carvan M.J., Crofton K.M., King K.A., Suñol C., Tiffany-Castiglioni E., Schultz I.R. Defining and modeling known adverse outcome pathways: domoic acid and neuronal signaling as a case study. Environ. Toxicol. Chem. 2011, 30:9-21.
49. Woolbright B.L., Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. World J. Gastroenterol. 2012, 18:4985-4993.
50. Yozzo K.L., McGee S.P., Volz D.C. Adverse outcome pathways during zebrafish embryogenesis: a case study with paraoxon. Aquat. Toxicol. 2013, 126:346-354.
51. Zimmerman H.J. Drug-induced liver disease. Clin. Liver Dis. 2000, 4:73-96.
52. Zollner G., Trauner M. Molecular mechanisms of cholestasis. Wien. Med. Wochenschr. 2006, 156:380-385.
53. Zollner G., Trauner M. Mechanisms of cholestasis. Clin. Liver Dis. 2008, 12:1-26.